Clinical Trial

Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine

Study acronym: SWITCH
Recruiting
View on ClinicalTrials.gov →
Summary
This project aims to investigate the impact of e-cigarette flavors and usage patterns on achieving harm-reduction milestones in a sample of cigarette smokers with opioid use disorder who are taking buprenorphine
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-13
notable Primary completion moved earlier: 2029-10-27 -> 2029-03-30 2026-04-17
minor Completion moved earlier: 2030-02-04 -> 2029-06-29 2026-04-17
Trial Details
NCT Number NCT07202039
Lead Sponsor Prisma Health-Upstate
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Tobacco-flavored EC, Sweet-Cooling EC, Sweet Non-cooling EC
Enrollment 90 participants
Start Date 2026-04-29
Primary Completion 2029-03-30 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-05-12